Several authors suggest the use of JAK inhibitors (JAKi) in the treatment of COVID-19 as in the case of Baricitinib, a JAK inhibitor targeting JAK1 and JAK2, mechanistically able to inhibit the signaling of many COVID-19-related cytokines (52). This evidence concerns the gene JAK1 and COVID-19.